JPMorgan Chase & Co. purchased a new position in shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 102,076 shares of the biotechnology company’s stock, valued at approximately $600,000. JPMorgan Chase & Co. owned about 0.23% of Pieris Pharmaceuticals at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the company. State Street Corp acquired a new position in shares of Pieris Pharmaceuticals in the second quarter worth approximately $2,377,000. Northern Trust Corp acquired a new position in shares of Pieris Pharmaceuticals in the second quarter worth approximately $1,625,000. TIAA CREF Investment Management LLC acquired a new position in shares of Pieris Pharmaceuticals in the second quarter worth approximately $649,000. Vanguard Group Inc. acquired a new position in shares of Pieris Pharmaceuticals in the second quarter worth approximately $526,000. Finally, First Quadrant L P CA acquired a new position in shares of Pieris Pharmaceuticals in the third quarter worth approximately $473,000. Institutional investors own 50.45% of the company’s stock.
In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $5.70, for a total value of $841,519.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.05% of the stock is currently owned by insiders.
Pieris Pharmaceuticals Inc (NASDAQ PIRS) opened at $7.46 on Tuesday. The company has a market capitalization of $334.17, a P/E ratio of -10.22 and a beta of -76.25. Pieris Pharmaceuticals Inc has a 12 month low of $1.66 and a 12 month high of $7.90.
Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. The company had revenue of $3.93 million for the quarter, compared to analyst estimates of $1.52 million. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. The firm’s quarterly revenue was up 400.3% on a year-over-year basis. equities research analysts predict that Pieris Pharmaceuticals Inc will post -0.72 EPS for the current fiscal year.
A number of equities analysts recently commented on the company. BidaskClub raised Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. HC Wainwright set a $9.00 price objective on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, December 20th. Finally, ValuEngine lowered Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.00.
COPYRIGHT VIOLATION WARNING: “JPMorgan Chase & Co. Purchases Shares of 102,076 Pieris Pharmaceuticals Inc (PIRS)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/16/jpmorgan-chase-co-purchases-shares-of-102076-pieris-pharmaceuticals-inc-pirs.html.
Pieris Pharmaceuticals Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Want to see what other hedge funds are holding PIRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pieris Pharmaceuticals Inc (NASDAQ:PIRS).
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.